GFAP and neuropathic pain: Yoshida et al. 57 demonstrated that the intrathecal application of anti-fibroblast growth factor-2 (FGF-2) antibodies, in a rat model of neuropathic pain, suppresses the increase of FGF-2 and GFAP positive cells and significantly attenuated the mechanical allodynia in rats.